MeSH term
Frequency | Condition_Probility | Adult | 118 | 0.0 |
Aged | 89 | 0.0 |
Aged, 80 and over | 44 | 0.0 |
Barrett Esophagus/*genetics | 2 | 25.0 |
*Base Pair Mismatch | 42 | 46.0 |
*DNA Repair | 53 | 7.0 |
DNA-Binding Proteins/analysis | 4 | 5.0 |
Female | 191 | 0.0 |
Humans | 369 | 0.0 |
Immunohistochemistry | 67 | 0.0 |
Male | 171 | 0.0 |
Middle Aged | 147 | 0.0 |
Neoplasm Proteins/analysis | 8 | 2.0 |
Proto-Oncogene Proteins/analysis | 10 | 5.0 |
Research Support, Non-U.S. Gov't | 246 | 0.0 |
Age of Onset | 17 | 1.0 |
Amino Acid Sequence | 22 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics/pathology | 4 | 40.0 |
DNA Mutational Analysis | 59 | 1.0 |
DNA, Neoplasm/chemistry/genetics | 3 | 2.0 |
*DNA-Binding Proteins | 151 | 8.0 |
Family Health | 13 | 1.0 |
Genotype | 15 | 0.0 |
Molecular Sequence Data | 59 | 0.0 |
Mutation | 41 | 0.0 |
Neoplasm Proteins/genetics | 35 | 7.0 |
Phenotype | 33 | 0.0 |
Proto-Oncogene Proteins/genetics | 34 | 6.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
Adenosinetriphosphatase/genetics/metabolism | 2 | 8.0 |
*Aneuploidy | 3 | 3.0 |
Animals | 66 | 0.0 |
*DNA Repair Enzymes | 30 | 31.0 |
DNA-Binding Proteins/genetics/metabolism | 7 | 1.0 |
Exons | 17 | 0.0 |
Mice | 51 | 0.0 |
Mice, Inbred C57BL | 14 | 0.0 |
Mice, Mutant Strains | 4 | 0.0 |
Microsatellite Repeats | 49 | 4.0 |
Neoplasm Proteins/genetics/metabolism | 6 | 5.0 |
Sequence Analysis | 2 | 0.0 |
*Germ-Line Mutation | 29 | 6.0 |
Microsatellite Repeats/genetics | 30 | 7.0 |
Neoplasm Proteins/biosynthesis/*genetics | 6 | 6.0 |
Predictive Value of Tests | 6 | 0.0 |
Proto-Oncogene Proteins/biosynthesis/*genetics | 6 | 9.0 |
Mammals | 2 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
Base Sequence | 48 | 0.0 |
Cell Line | 11 | 0.0 |
Chromosome Aberrations | 3 | 0.0 |
DNA Mutational Analysis/*methods | 5 | 3.0 |
Genes, BRCA1 | 3 | 1.0 |
Polymerase Chain Reaction/*methods | 7 | 1.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Sensitivity and Specificity | 18 | 0.0 |
Sequence Deletion | 8 | 0.0 |
Tumor Cells, Cultured | 19 | 0.0 |
Alleles | 18 | 0.0 |
Colorectal Neoplasms/*genetics | 19 | 8.0 |
Endometrial Neoplasms/*genetics | 5 | 10.0 |
Germ-Line Mutation | 32 | 8.0 |
*Microsatellite Repeats | 25 | 11.0 |
Phosphoric Monoester Hydrolases/genetics | 2 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 110 | 0.0 |
Trinucleotide Repeat Expansion | 2 | 5.0 |
Tumor Suppressor Proteins/genetics | 2 | 2.0 |
DNA/*metabolism | 2 | 0.0 |
DNA Damage | 8 | 0.0 |
Models, Biological | 4 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 14 | 0.0 |
Base Pair Mismatch | 51 | 30.0 |
DNA Repair | 56 | 8.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics | 50 | 52.0 |
DNA-Binding Proteins/*genetics/physiology | 3 | 3.0 |
Mutation, Missense | 6 | 0.0 |
Proto-Oncogene Proteins/physiology | 3 | 2.0 |
Adolescent | 16 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
DNA, Neoplasm/*genetics | 7 | 3.0 |
DNA-Binding Proteins/metabolism | 8 | 0.0 |
Disease-Free Survival | 5 | 0.0 |
Drug Resistance, Neoplasm | 5 | 0.0 |
Microsatellite Repeats/*genetics | 30 | 11.0 |
Neoplasm Proteins/metabolism | 7 | 1.0 |
Proto-Oncogene Proteins/metabolism | 6 | 0.0 |
Base Pair Mismatch/*genetics | 24 | 43.0 |
Neoplasms, Multiple Primary/*genetics | 3 | 7.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
Gene Expression | 11 | 0.0 |
Mutagenesis | 10 | 0.0 |
Case-Control Studies | 6 | 0.0 |
DNA Repair/*genetics | 56 | 17.0 |
*Gene Expression Profiling | 2 | 0.0 |
Proto-Oncogene Proteins/genetics/metabolism | 7 | 3.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Cell Cycle | 3 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Gene Library | 3 | 0.0 |
Hela Cells | 11 | 0.0 |
Models, Genetic | 8 | 0.0 |
Oligonucleotide Array Sequence Analysis | 4 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 10 | 0.0 |
Phosphorylation | 4 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 11 | 1.0 |
Neoplasm Proteins/analysis/*genetics | 4 | 12.0 |
Proto-Oncogene Proteins/analysis/*genetics | 4 | 8.0 |
DNA, Neoplasm/genetics | 11 | 1.0 |
Germ-Line Mutation/*genetics | 15 | 9.0 |
Neoplasm Proteins/*genetics | 61 | 5.0 |
Pedigree | 51 | 0.0 |
Polymerase Chain Reaction | 43 | 0.0 |
Proto-Oncogene Proteins/*genetics | 78 | 8.0 |
Follow-Up Studies | 7 | 0.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Neoplasm Proteins/*biosynthesis/genetics | 3 | 1.0 |
Neoplasm Staging | 10 | 0.0 |
Prognosis | 15 | 0.0 |
Survival Analysis | 9 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
*DNA Mutational Analysis | 3 | 1.0 |
Polymorphism, Genetic | 6 | 0.0 |
Sequence Analysis, DNA | 13 | 0.0 |
Time Factors | 6 | 0.0 |
*Arabidopsis Proteins | 2 | 2.0 |
Base Pair Mismatch/genetics | 18 | 40.0 |
Blotting, Southern | 5 | 0.0 |
Phylogeny | 2 | 0.0 |
Recombination, Genetic | 6 | 0.0 |
Saccharomyces cerevisiae/genetics | 5 | 1.0 |
Sequence Homology | 2 | 0.0 |
Endometrial Neoplasms/*genetics/pathology | 5 | 15.0 |
English Abstract | 13 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*pathology | 2 | 100.0 |
Neoplasm Proteins/*analysis | 4 | 1.0 |
Proto-Oncogene Proteins/*analysis/genetics | 2 | 6.0 |
Colorectal Neoplasms/genetics | 4 | 9.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics | 19 | 44.0 |
DNA Repair/genetics | 29 | 17.0 |
*Gene Deletion | 8 | 0.0 |
Adenoma/*pathology | 2 | 9.0 |
Disease Progression | 5 | 0.0 |
DNA/*genetics | 2 | 0.0 |
DNA Transposable Elements | 2 | 1.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Meiosis | 3 | 2.0 |
*Proto-Oncogene Proteins | 10 | 0.0 |
DNA-Binding Proteins/*genetics | 44 | 2.0 |
Gene Expression Regulation, Neoplastic | 10 | 0.0 |
*Gene Rearrangement | 2 | 0.0 |
Gene Silencing | 3 | 0.0 |
Point Mutation | 11 | 0.0 |
Polymerase Chain Reaction/methods | 6 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
DNA/genetics | 7 | 0.0 |
*Immunoglobulin Class Switching | 5 | 38.0 |
In Vitro | 2 | 0.0 |
Mice, Knockout | 18 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
*Drosophila Proteins | 2 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 4 | 1.0 |
*Multidrug Resistance-Associated Proteins | 17 | 31.0 |
Binding Sites | 5 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics/*metabolism | 3 | 100.0 |
Protein Binding | 11 | 0.0 |
Adenosinetriphosphatase/metabolism | 3 | 2.0 |
Mutation/*genetics | 11 | 0.0 |
Neoplasm Proteins/*genetics/metabolism | 8 | 5.0 |
DNA, Neoplasm/analysis | 19 | 2.0 |
Immunoenzyme Techniques | 13 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
Sequence Analysis, DNA/methods | 2 | 2.0 |
Colorectal Neoplasms/epidemiology/*genetics | 2 | 15.0 |
Endometrial Neoplasms/epidemiology/*genetics | 2 | 50.0 |
*Heterozygote | 7 | 2.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
Colorectal Neoplasms/*genetics/pathology | 7 | 8.0 |
*Genetic Predisposition to Disease | 16 | 1.0 |
*Mutation, Missense | 6 | 1.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics/*pathology | 3 | 100.0 |
DNA Replication/*genetics | 2 | 3.0 |
Frameshift Mutation/genetics | 2 | 2.0 |
Intestinal Mucosa/pathology | 3 | 5.0 |
Skin Neoplasms/*genetics/pathology | 3 | 5.0 |
DNA-Binding Proteins/genetics | 16 | 1.0 |
Fungal Proteins/genetics | 5 | 3.0 |
*Genes, Tumor Suppressor | 3 | 0.0 |
Plasmids | 2 | 0.0 |
Receptors, Transforming Growth Factor beta/genetics | 2 | 3.0 |
*Saccharomyces cerevisiae Proteins | 25 | 2.0 |
Proto-Oncogene Proteins/deficiency/genetics | 3 | 60.0 |
Child | 10 | 0.0 |
Rectal Neoplasms/*genetics/pathology | 2 | 22.0 |
Syndrome | 5 | 0.0 |
*Genetic Counseling | 2 | 4.0 |
Prospective Studies | 6 | 0.0 |
Stress, Psychological | 2 | 7.0 |
*Acid Anhydride Hydrolases | 5 | 2.0 |
Multivariate Analysis | 5 | 0.0 |
Proto-Oncogene Proteins/*biosynthesis | 8 | 5.0 |
Comparative Study | 40 | 0.0 |
Retrospective Studies | 4 | 0.0 |
*DNA Methylation | 2 | 0.0 |
Age Factors | 10 | 0.0 |
Child, Preschool | 3 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/epidemiology/*genetics | 6 | 75.0 |
Heterozygote | 16 | 0.0 |
*Mutation | 29 | 0.0 |
Netherlands/epidemiology | 2 | 1.0 |
Registries | 3 | 1.0 |
Risk Factors | 17 | 0.0 |
Sex Factors | 6 | 0.0 |
Fungal Proteins/*genetics | 13 | 10.0 |
Gene Deletion | 11 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
*Trinucleotide Repeat Expansion | 2 | 4.0 |
*Escherichia coli Proteins | 3 | 1.0 |
Mice, Transgenic | 6 | 0.0 |
*Mutagenesis | 3 | 5.0 |
Repressor Proteins/genetics | 2 | 1.0 |
Genes, APC | 3 | 3.0 |
Genes, p53 | 6 | 1.0 |
Rectal Neoplasms/*genetics/metabolism/pathology | 2 | 100.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
Genetic Predisposition to Disease | 18 | 0.0 |
Genetic Screening | 16 | 1.0 |
Incidence | 10 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics | 7 | 5.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 8 | 9.0 |
Analysis of Variance | 2 | 0.0 |
Gene Frequency | 3 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Saccharomyces cerevisiae/*genetics | 12 | 7.0 |
Neoplasm Proteins/*metabolism | 6 | 1.0 |
Loss of Heterozygosity | 14 | 1.0 |
Antimetabolites, Antineoplastic/pharmacology | 3 | 3.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Ovarian Neoplasms/*genetics | 3 | 0.0 |
Receptors, Transforming Growth Factor beta/*genetics | 2 | 4.0 |
Exons/genetics | 6 | 0.0 |
Ploidies | 3 | 1.0 |
Fungal Proteins/*physiology | 2 | 8.0 |
Ovarian Neoplasms/genetics | 5 | 3.0 |
Risk Assessment | 5 | 0.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
Neoplasm Proteins/*biosynthesis | 4 | 4.0 |
Neoplasms, Multiple Primary/*genetics/pathology | 2 | 20.0 |
Genetic Screening/methods | 5 | 4.0 |
Breast Neoplasms/*genetics | 3 | 0.0 |
DNA/chemistry/genetics | 3 | 0.0 |
*Frameshift Mutation | 5 | 2.0 |
Fatal Outcome | 2 | 0.0 |
Germ-Line Mutation/genetics | 5 | 7.0 |
Diagnosis, Differential | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Netherlands | 3 | 1.0 |
Penetrance | 2 | 1.0 |
Colonic Neoplasms/*genetics/pathology | 2 | 4.0 |
Genes, p53/genetics | 3 | 1.0 |
Genes, ras/genetics | 5 | 4.0 |
Statistics, Nonparametric | 2 | 0.0 |
*Adenosinetriphosphatase | 18 | 24.0 |
Colonic Neoplasms/genetics | 6 | 9.0 |
Endometrial Neoplasms/genetics | 5 | 31.0 |
Rectal Neoplasms/genetics | 2 | 22.0 |
Stomach Neoplasms/genetics | 4 | 16.0 |
Urologic Neoplasms/genetics | 2 | 100.0 |
DNA Primers | 8 | 0.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
*Gene Conversion | 3 | 9.0 |
Repetitive Sequences, Nucleic Acid | 4 | 0.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Gene Frequency/genetics | 3 | 0.0 |
Loss of Heterozygosity/genetics | 3 | 2.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
United States | 3 | 0.0 |
Dimerization | 3 | 0.0 |
Tumor Markers, Biological/*biosynthesis | 2 | 2.0 |
Adenomatous Polyposis Coli Protein | 2 | 2.0 |
Polymorphism, Single-Stranded Conformational | 14 | 0.0 |
Signal Transduction | 2 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics/pathology | 4 | 57.0 |
*Loss of Heterozygosity | 5 | 1.0 |
Gene Expression Profiling | 3 | 0.0 |
DNA Mutational Analysis/methods | 5 | 2.0 |
Sequence Analysis, RNA/*methods | 2 | 40.0 |
*Sequence Deletion | 3 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Cadherins/*biosynthesis | 2 | 6.0 |
Cytoskeletal Proteins/*biosynthesis | 2 | 11.0 |
*Immunohistochemistry | 2 | 2.0 |
Neoplasm Metastasis | 2 | 0.0 |
Linkage (Genetics) | 9 | 0.0 |
Lymphatic Metastasis | 5 | 0.0 |
Heteroduplex Analysis | 2 | 2.0 |
*Recombination, Genetic | 9 | 2.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 5 | 1.0 |
*DNA Damage | 6 | 1.0 |
Protein Biosynthesis | 5 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis/*genetics | 11 | 91.0 |
Genetic Screening/*methods | 4 | 2.0 |
Proto-Oncogene Proteins/analysis/genetics | 6 | 21.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 3 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Risk | 2 | 0.0 |
Chromosomes, Human, Pair 2/genetics | 4 | 2.0 |
Frameshift Mutation | 7 | 1.0 |
Hybrid Cells | 3 | 0.0 |
Mutagenesis, Insertional | 3 | 1.0 |
Adenosinetriphosphatase/*genetics | 3 | 3.0 |
Cloning, Molecular | 9 | 0.0 |
DNA Helicases/*genetics | 2 | 4.0 |
Ultraviolet Rays | 5 | 0.0 |
Genetic Markers | 8 | 0.0 |
Tumor Markers, Biological/analysis | 4 | 0.0 |
Mutation, Missense/genetics | 3 | 1.0 |
Dacarbazine/*analogs & derivatives/pharmacology | 2 | 18.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
Colonic Neoplasms/*genetics | 3 | 3.0 |
Mutation/genetics | 9 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Protein-Serine-Threonine Kinases/genetics | 2 | 1.0 |
Proteins/genetics | 12 | 1.0 |
Variation (Genetics) | 2 | 0.0 |
BRCA2 Protein | 4 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Consensus Sequence | 2 | 0.0 |
Fungal Proteins/metabolism | 4 | 2.0 |
Proliferating Cell Nuclear Antigen/*metabolism | 2 | 1.0 |
Saccharomyces cerevisiae | 4 | 1.0 |
Sequence Alignment | 7 | 0.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Haplotypes | 5 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
History, 19th Century | 3 | 10.0 |
History, 20th Century | 3 | 2.0 |
DNA/analysis | 2 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
Crosses, Genetic | 4 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Mutagenesis/*genetics | 3 | 11.0 |
Proteins/genetics/*metabolism | 4 | 0.0 |
Neoplastic Syndromes, Hereditary/genetics | 2 | 6.0 |
Evolution, Molecular | 2 | 0.0 |
*Founder Effect | 5 | 4.0 |
Haplotypes/genetics | 2 | 0.0 |
Introns | 5 | 0.0 |
*Genes, Fungal | 7 | 6.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Finland/epidemiology | 2 | 1.0 |
B-Lymphocytes/cytology/immunology | 2 | 6.0 |
Cytidine Deaminase/metabolism | 2 | 18.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
DNA-Directed DNA Polymerase/metabolism | 3 | 9.0 |
*Somatic Hypermutation, Immunoglobulin | 2 | 20.0 |
Herpesvirus 4, Human/genetics | 2 | 2.0 |
DNA Methylation | 4 | 0.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
Cell Cycle Proteins/metabolism | 4 | 1.0 |
*Nuclear Proteins | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Neoplasm Proteins/analysis/*biosynthesis | 2 | 20.0 |
Proto-Oncogene Proteins/analysis/*biosynthesis | 2 | 8.0 |
Colorectal Neoplasms/diagnosis/*genetics | 3 | 33.0 |
Genome, Human | 2 | 0.0 |
*Linkage Disequilibrium | 2 | 1.0 |
DNA Primers/genetics | 2 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Fungal Proteins/*genetics/physiology | 2 | 22.0 |
Aneuploidy | 2 | 1.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Tumor Markers, Biological | 2 | 0.0 |
DNA Repair/*physiology | 2 | 1.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Proto-Oncogene Proteins/*genetics/*metabolism | 2 | 4.0 |
Bacterial Proteins/*genetics | 2 | 3.0 |
DNA, Complementary/genetics | 4 | 0.0 |
DNA-Binding Proteins/*biosynthesis | 5 | 4.0 |
Meiosis/genetics | 2 | 6.0 |
Rats | 4 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 3 | 0.0 |
Esophageal Neoplasms/*genetics | 3 | 4.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
*Sequence Homology, Nucleic Acid | 2 | 2.0 |
Portugal | 2 | 3.0 |
Chromosomes, Human, Pair 2/*genetics | 3 | 1.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Trinucleotide Repeats | 2 | 1.0 |
Genetic Predisposition to Disease/*genetics | 4 | 1.0 |
Great Britain/epidemiology | 2 | 1.0 |
Survival Rate | 5 | 0.0 |
DNA-Binding Proteins/analysis/genetics | 2 | 11.0 |
Neoplasm Proteins/analysis/genetics | 3 | 12.0 |
Genetic Markers/genetics | 2 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*diagnosis/genetics | 2 | 100.0 |
Genetic Techniques | 2 | 2.0 |
*Genetic Screening | 7 | 3.0 |
DNA, Satellite/genetics | 2 | 1.0 |
Genetic Complementation Test | 4 | 0.0 |
Neoplasm Proteins | 3 | 9.0 |
Proteins/metabolism | 2 | 0.0 |
*Disease Models, Animal | 2 | 0.0 |
Cell Survival | 3 | 0.0 |
Chromosome Mapping | 7 | 0.0 |
Gene Amplification | 2 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
*Carrier Proteins | 5 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Immunoglobulin Class Switching/*genetics | 2 | 20.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/ethnology/*genetics | 2 | 66.0 |
Proteins/*genetics | 4 | 0.0 |
*Genes, p53 | 3 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Colon/*pathology | 2 | 12.0 |
Italy/epidemiology | 3 | 1.0 |
Colorectal Neoplasms/*genetics/metabolism | 2 | 6.0 |
Gene Expression Regulation, Fungal | 2 | 2.0 |
Methylation | 4 | 0.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Hamsters | 4 | 0.0 |
Founder Effect | 2 | 1.0 |
Cell Differentiation | 3 | 0.0 |
Codon | 3 | 0.0 |
DNA Replication/genetics | 3 | 5.0 |
Neoplasms/genetics | 3 | 2.0 |
Yeasts/genetics | 2 | 2.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Cisplatin/pharmacology | 3 | 1.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Mass Screening | 2 | 1.0 |
Frameshift Mutation/*genetics | 2 | 3.0 |
Repetitive Sequences, Nucleic Acid/*genetics | 2 | 1.0 |
Endometrial Neoplasms/complications/*genetics | 2 | 66.0 |
Genetic Counseling | 3 | 1.0 |
*Chromosome Mapping | 3 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Protein p53/metabolism | 3 | 0.0 |
CHO Cells | 2 | 0.0 |
*Nucleic Acid Heteroduplexes | 2 | 13.0 |
*Trinucleotide Repeats | 2 | 1.0 |
DNA Replication | 5 | 1.0 |
DNA-Binding Proteins | 3 | 3.0 |
Genomic Instability | 5 | 31.0 |
Genes, ras | 4 | 1.0 |
*Neoplasm Proteins | 4 | 0.0 |
Species Specificity | 2 | 0.0 |
DNA, Neoplasm | 2 | 1.0 |
DNA-Binding Proteins/*genetics/metabolism | 8 | 1.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 5 | 3.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Colorectal Neoplasms/*genetics/*pathology | 2 | 8.0 |
Genes, Tumor Suppressor | 3 | 0.0 |
Lymphoma/*genetics | 2 | 4.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 2 | 1.0 |
Statistics | 2 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Adenosine Triphosphate/*metabolism | 2 | 2.0 |
Hydrolysis | 2 | 0.0 |
Oligonucleotide Probes/genetics | 2 | 1.0 |
Codon/genetics | 2 | 0.0 |
DNA-Binding Proteins/deficiency/genetics | 3 | 13.0 |
Disease Susceptibility | 5 | 0.0 |
*Chromosomes, Human, Pair 2 | 3 | 1.0 |
Proto-Oncogene Proteins/*physiology | 3 | 1.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Transfection | 3 | 0.0 |
Probability | 3 | 0.0 |
*Fungal Proteins | 7 | 20.0 |
*Schizosaccharomyces pombe Proteins | 2 | 2.0 |
Nucleic Acid Heteroduplexes | 3 | 6.0 |
Substrate Specificity | 2 | 0.0 |
Nucleic Acid Heteroduplexes/*genetics | 2 | 15.0 |
Fungal Proteins/*metabolism | 3 | 3.0 |
Models, Molecular | 2 | 0.0 |
Lymphoma, Lymphoblastic/*genetics/pathology | 2 | 100.0 |
Chromosomes, Human, Pair 2 | 4 | 2.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
DNA, Complementary | 2 | 0.0 |
Genes, Fungal | 2 | 1.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
DNA/metabolism | 2 | 0.0 |
Protein p53/genetics/*metabolism | 2 | 1.0 |
Mitosis | 2 | 0.0 |
DNA-Binding Proteins/*analysis | 2 | 3.0 |
Proto-Oncogene Proteins/*analysis | 2 | 1.0 |
*Repetitive Sequences, Nucleic Acid | 4 | 1.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
*Genes, APC | 2 | 2.0 |
Cohort Studies | 7 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
*Caenorhabditis elegans Proteins | 5 | 4.0 |
Colonoscopy | 2 | 4.0 |
Protein p53/genetics | 3 | 1.0 |
Family | 3 | 0.0 |
*Homozygote | 2 | 1.0 |
Proto-Oncogene Proteins/deficiency/genetics/*metabolism | 2 | 22.0 |
*DNA Repair/drug effects | 2 | 40.0 |
Kinetics | 2 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*diagnosis | 2 | 100.0 |
Finland | 2 | 0.0 |
Sex Distribution | 3 | 1.0 |
Cost-Benefit Analysis | 4 | 3.0 |
Carcinoma/*genetics | 2 | 1.0 |
Adenosinetriphosphatase/*genetics/metabolism | 2 | 7.0 |
Mass Screening/methods | 2 | 4.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Age Distribution | 2 | 0.0 |
Genetic Predisposition to Disease/*ethnology | 2 | 16.0 |
Jews/*genetics | 4 | 2.0 |
United States/epidemiology | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Protein p53/biosynthesis | 2 | 1.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*epidemiology/*genetics | 2 | 66.0 |
Heterozygote Detection | 3 | 0.0 |